- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Elaine H. Tseng
News 3 results
Cases & Deals
September 27, 2016
King & Spalding Advises EndoChoice in $210 Million Sale to Boston Scientific
Cases & Deals
July 20, 2016
King & Spalding Advises Jounce Therapeutics on Deal Worth Up to $2.5 Billion
Cases & Deals
September 17, 2015
King & Spalding Advises Nurix in $150 Million-Plus Drug Collaboration and Option Deal with Celgene
Events 19 results
Webinar
April 20, 2022
Regulation of Cell and Gene Therapies: An Overview
Webinar
January 25, 2022
2021 Year in Review for Drug and Device Advertising and Promotion – Lessons Learned From FDA Enforcement Letters and Other Key Developments
Speaking Engagement
December 15, 2021
Eva Temkin, Elaine Tseng to Speak at AFDLI Food and Drug Law Institute Conference
Webinar
November 9, 2021
King & Spalding Pharmaceutical University 2021
Insights 36 results
Client Alert
March 10, 2022
France - A Charter for the Promotion of Medical Devices (Including IVD)
Client Alert
March 1, 2022
The Wait is Over: FDA Releases Proposed Rule to Align the U.S. Medical Device Quality Regulation with International Standards
Client Alert
February 7, 2022
A Pandemic Silver Lining: FDA’s New Guidance on Using Digital Health Technologies for Clinical Investigations
Client Alert
November 9, 2021
A Magic Mixing Cauldron for the 21st Century: FDA’s new guidances on using real-world data in regulatory decision-making